China: GTJA pilots $39m round in antibody drug firm Mabworks Tomas S. Noda III January 24, 2017 PremiumChinese private equity firm Shenzhen GTJA Investment Group has piloted a $39 million (RMB270) series B round in Mabworks Biotech Co Ltd, a Beijing-based developer of gene engineering antibody medicines. Continue reading this story with a subscription to DealStreetAsia. Subscribe Already a subscriber? Log in Should your colleagues be reading this article too? Contact us for corporate subscriptions at firstname.lastname@example.org.